Tag Archives: Digital Health

Hot Investor Mandate 2: USA-Based Venture Capital Firm Invests in Medical Devices, Diagnostics, and Digital Health with Strong Interests in Applications of AI and Machine Learning

28 Jun

A venture capital company founded in 2005 and located in California manages just under $70 million in assets across 2 funds and makes equity investments into companies ranging from a few hundred thousand dollars to $2 million with additional capital reserved for follow on rounds. The firm is looking for companies located throughout the United States and plans to make 4 new investments over the next 6-9 months.

The firm is looking for companies developing Medical Devices and Diagnostics, Healthcare IT products and Life Science Research Tools with an emphasis on fast to market low capital intense products that reduce the cost of delivering quality healthcare. For Healthcare IT investments the firm is most interested in machine learning and artificial intelligence (AI) applications and is generally not interested in Telehealth and EMR solutions. The firm is open to all sub-sectors and indications in the Medical technology space except for those targeting diseases and disorders of the spine. The firm will invest in both seed and later stage companies.

The firm is looking for companies with skilled and experienced management teams. The firm generally looks to take a board seat into companies after investment and play and active role in the management. The firm is willing to invest in both public and privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: VC Firm Seeks Investment Opportunities in Digital Health and Medical Device Technologies that Address Problems of Large Unmet Need in Healthcare

28 Jun

A venture capital firm spun out of a leading university looks to provide primarily seed stage financings to companies ranging from $100K – $500k initially with up to $5-6 million provided over the lifetime of the investment. The firm prefers to invest in companies in the Eastern United States but is open to considering companies from around the globe. The firm could make as many as 6-7 investments over the next 6-9 months.

The firm is looking for companies working in sectors of digital health and more selectively medical devices. The firm is only interested in companies that are targeting very larger markets/unmet needs and is not interested in companies that require FDA Approval. The firm is especially interested in companies utilizing software for the optimization of various products and processes within healthcare. The firm is not interested in consumer-facing products.

The firm is very open to working with young entrepreneurs and generally looks to take a board seat following the investment. The firm is looking for companies with the potential to become very large organizations capable of being worth hundreds of millions of dollars.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Japanese Pharmaceutical Seeks to Partner with Global Innovations in Therapeutics, Devices, Digital Health with Focus in Orthopedics, Respiratory, Cardivascular Diseases

21 Jun

A pharmaceutical company headquartered in Tokyo, Japan, focuses on two main sectors: pharmaceutical and medical device for home healthcare. The company is seeking innovative medical technologies to strengthen its pipeline while expanding into new areas. The company is looking for in-licensing and collaborative R&D opportunities in the US, Canada, EU, and Israel.

The company has existing businesses in respiratory diseases, cardiovascular diseases, and orthopedics. The firm is seeking innovative, home-care, therapeutic medical devices in the disease sectors described above. The company is also interested in home patient monitoring products. In addition, the company is looking for innovations in the following areas: neurological disorders such as stroke, depression, Parkinson’s disease, etc.; cancer; wound care; and rehabilitation, which all must be used at home care. The company is most interested in PMA and de novo therapeutic devices in the home-care settings. The company prefers assets with initial patient data. Furthermore, the company is seeking opportunities in digital medicine business (but not for consumer products) in disease areas described above.

Within pharmaceuticals, the company had previously focused on late clinical stage assets in orthopedics, respiratory diseases, and cardiovascular diseases, but has expanded interests to consider early-stage opportunities. The company is most interested in small molecule and peptide drugs.

The company is looking for assets that are a compliment to its portfolio. The company prefers to own rights in the Japan market, while its partners can keep US or EU rights. The company’s regulatory team, clinical team and support system can assist its partners with product registration and distribution in Japan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: China-Based VC Firm Can Invest Up to $50M in Life Science Companies, Including Therapeutics, Medical Devices, Diagnostics, and Digital Health

14 Jun

A venture firm based in China with offices in the West and East Coast currently funds healthcare companies out of their $3.5B fund. The firm is interested in companies raising their seed to Series A rounds and provides investments that can range from $5M to $50M depending on the opportunity. The firm seeks opportunities globally, though has a preference on companies based in China.

The firm is interested in therapeutics, medical devices without drug components, in-vitro diagnostics, and healthcare IT. The firm is interested in preclinical to early-stage clinical (Ph I-II) technologies. The firm is indication agnostic, though highly prefers technology with a China market angle.

The firm does not have a management team requirement, and will help support early-stage companies with filling management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: USA Venture Firm Seeks to Invest in Innovative Digital Health and Software-Based Diagnostic Companies

14 Jun

A venture capital firm with multiple offices in the USA is looking to invest in tech-driven companies that have at least one female on the leadership team. The firm invests in technology companies, including those in the healthcare sector, such as digital health and software-based diagnostics companies. The firm will invest primarily in series A-B rounds in USA-based companies with at least $1M in revenue. The firm will typically make initial investments between $1.5-5M.

The firm invests in technology companies in the digital health space that are solving some of the world’s greatest challenges. The firm particularly likes to see companies that are creating more affordable health solutions.

The firm does not require a board seat when investing, but may take one if the firm leads an investment round.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Taiwan Cross Border VC Seeks Medical Devices, Diagnostic Tools, Digital Health, Healthcare IoT Technologies

7 Jun

An early-stage venture capital firm based in Taipei, Taiwan is actively investing in the life sciences space. Formed by a group of successful entrepreneurs, the firm specializes in incubation, seed and early venture investments in technology-heavy sectors. The firm is currently investing from its $35 million fund that closed in 2016. Typical equity allocations range from $500K to $3M in seed to series A rounds. The firm generally leads a financing round but is also open to syndication. The firm is currently seeking opportunities from Taiwan and the United States.

Within life sciences, the firm considers medical devices, IVD tools, digital health and healthcare internet of things (IoT). Within medtech, the firm is looking for early stage projects with solid unmet medical need. On-market products are less of interest. The firm is open to all risk levels and all disease indications. The firm is also interested in material science and agricultural biotech.

The firm is an active investor. The firm can work with incomplete teams, assist companies with regulatory strategy and product definition, and help overseas businesses find manufacturing partners in Taiwan. The firm typically takes a board seat in a portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Joint Initiative Launched by a Leading Pharma and VC Firm Invests in Digital Health Companies with USA Focus

7 Jun

A digital health investment company launched in 2016 by a leading pharma and venture capital firm in the industry focuses on the digital health space ranging from therapeutics to diagnostic solutions in areas such as: precision medicine, behavioral health, wearables, and data analytics. The firm is seeking to make 6-8 new investments within the next two years. The firm’s investments range dependent on the opportunity, and focuses on investing in Seed to Series A rounds. For earlier stage companies, the firm has the ability to both lead and co-invest. The firm focuses on companies based in the U.S., but is open to invest globally.

The firm focuses on digital health technologies and solutions that aim to improve patient care and lifestyle. The firm is especially interested in technology with a software component, such as those that control patient care through monitoring medications and therapies, as well as technology with a big data component. The firm will only look at devices if they have an information component and/or generate data. The firm is also interested in technology with machine-learning applications. The firm is not interested in pure EMR or hospital IT systems. Based on all the criteria, the firm is indication agnostic.

The firm is a very active investor that seeks to be fully involved in their portfolio companies. The firm will take a board seat after the investment and will help companies fill management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: